Drug Trial Radar · NCT02531516
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,503
Actual
Start
Nov 19, 2015
Primary completion
Mar 1, 2027
Study completion Dec 29, 2028
Sponsor
- Lead sponsor
- Aragon Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).
Conditions
- Prostatic Neoplasms
Interventions
ApalutamideDrug
BicalutamideDrug
Bicalutamide PlaceboDrug
Apalutamide PlaceboDrug
GnRH (agonist)Drug
74-80 Grays (units of radiation)Radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Metastasis-Free Survival (MFS)Time frame: 108 Months
Locations
263 sites in 23 countries. Site status is shown where the registry gives one.
Site not named
Homewood, Alabama
Site not named
Chandler, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Bakersfield, California
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Middlebury, Connecticut
Site not named
Bradenton, Florida
Site not named
Daytona Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Hialeah, Florida
Site not named
Lakewood Rch, Florida
Site not named
Naples, Florida
Site not named
Plantation, Florida
Site not named
Meridian, Idaho
Site not named
Evergreen Park, Illinois
Site not named
Harvey, Illinois
Site not named
Jeffersonville, Indiana
Site not named
Wichita, Kansas
Site not named
Ashland, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Scarborough, Maine
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
St Louis, Missouri
Site not named
Morristown, New Jersey
Site not named
Albany, New York
Site not named
Brooklyn, New York
Site not named
New York, New York
Site not named
Poughkeepsie, New York
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
The Bronx, New York
Showing 40 of 263 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.